CEO Neil Kumar sold 26,103 shares for $1.8M (blended avg $69.44) on 2026-05-21 under pre-arranged 10b5-1 plan.
CEO Neil Kumar executed five separate sales totaling 26,103 shares for $1,812,521.76 on a single trading date, reducing his holdings by 9.7% to 243,327 shares. This transaction was scheduled under a pre-arranged 10b5-1 trading plan adopted on 2025-03-31, meaning it was not a discretionary decision but part of a predetermined execution schedule. The stock currently trades at $67.73, down 20.3% from its 52-week high of $84.94 and off 7.6% over the past 30 days, though it has gained 1.8% over 90 days. BridgeBio remains unprofitable with a $-166.6M net loss in the most recent quarter against $194.5M in revenue, though the company has achieved 126.3% annual revenue growth. Since this sale was scheduled rather than discretionary, it does not signal conviction or concern about near-term valuation; investors should focus instead on the company's fundamental trajectory as a high-growth but currently loss-making pharma organization.
BridgeBio CFO Thomas Trimarchi sells 13,651 shares for $888.4K via scheduled 10b5-1 plan on 2026-05-18
Thomas Trimarchi, President and CFO of BridgeBio Pharma, executed two separate sales totaling 13,651 shares for $888,419.17 on 2026-05-18, reducing his holdings by 3.7% to 359,194 shares post-transaction. The sales were executed through a pre-arranged 10b5-1 trading plan adopted on 2025-03-31, meaning the transactions were scheduled rather than discretionary. At BBIO specifically, Trimarchi's prior four measurable sales show mixed outcomes: two sales in February 2026 experienced 30-day declines of 6.2% and 7.0%, while two November 2025 sales saw 30-day gains of 11.8% and 10.7%. The company's fundamentals remain challenged: full-year net income was $-166.6M against quarterly revenue of $194.5M, though annual revenue growth reached +126.3%. Stock price is currently -22.3% from its 52-week high and down 14.0% over 30 days, reflecting the unprofitable operational status despite strong top-line expansion.
BridgeBio CEO Kumar Neil sells ~$5.4M of stock (80,000 shares) via 12 transactions; his 126th-137th open-market sale in 3 years, no purchases.
Kumar Neil, BridgeBio's CEO, sold approximately 80,000 shares over two trading days in early May totaling roughly $5.4M—his 126th through 137th open-market sale in the past three years, with zero open-market purchases in that period. The stock currently trades roughly 15% below its 52-week high and has declined modestly over the past three months, creating a backdrop where the CEO is choosing to reduce his position. His five prior sales at BridgeBio were all followed by stock declines, demonstrating consistent timing accuracy on those exits. The company is unprofitable on an annual basis, though quarterly results show a modest loss, alongside strong revenue growth that has more than doubled year-over-year, suggesting a cash-intensive growth business. The sale itself is not unusual for a pharmaceutical company burning cash, but the three-year pattern of continuous selling and complete absence of any open-market purchases is noteworthy for someone running the company—it reflects a persistent divestiture posture rather than conviction in the business or willingness to put personal capital at risk.
Add BBIO to your watchlist and we'll email you when an insider files a Form 4 — with our AI's significance score and a plain-English read of what it means.
